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Background: To test the hypotheses that breast cancer patients with one to three positive lymph nodes (pN1) consist of
heterogeneous prognostic subsets and that the ratio of positive nodes to total nodes dissected (lymph node ratio, LNR) might
discriminate patients with a higher risk as candidates for post-mastectomy radiation therapy (PMRT).
Methods: Using information from 7741 node-positive patients, we first identified cutoff values of the LNR using the nonparametric
bootstrap method. Focusing on 3477 patients with pN1 disease, we then evaluated the clinical relevance of the LNR categorised
by the estimated cutoff values (categorised LNR, cLNR).
Results: Among 3477 patients with pN1 disease, 3059 and 418 patients were assigned into the low and intermediate cLNR groups,
respectively, based on a cutoff value of 0.18. The prognostic factors associated with poor overall survival (OS) included younger
age, T2 stage, negative oestrogen/progesterone receptors, high histologic grade, and intermediate cLNR. Post-mastectomy
radiation therapy significantly increased OS in patients assigned to the intermediate cLNR (hazard ratio, 0.39; 95% confidence
interval, 0.17–0.89; P¼ 0.0248), whereas patients in the low cLNR group derived no additional survival benefit from PMRT.
Conclusion: This study suggests that PMRT should be recommended for patients with pN1 disease and an intermediate cLNR.
The staging system of breast cancer allows physicians to estimate
the prognosis of patients and guides treatment planning. Since the
sixth edition of the American Joint Committee on Cancer (AJCC)
staging system, patients with one to three positive axillary lymph
nodes have been defined as having positive lymph nodes (pN1)
disease (Singletary et al, 2002; Edge, 2010). Although the AJCC
staging system reflects the disease state by emphasising the
prognostic importance of the absolute number of affected lymph
nodes (Kim et al, 2006), the rationale behind four nodes as the
cutoff between pN1 and pN2 is unclear. Recently, the ratio of the
number of pN1 to the number of total dissected lymph nodes
(lymph node ratio, LNR) has been proposed as an alternative
prognostic factor instead of the absolute number of positive nodes
(Vinh-Hung et al, 2003a, b; Voordeckers et al, 2004; Truong et al,
2005a; Kuru, 2006; Woodward et al, 2006; Truong et al, 2008;
Vinh-Hung et al, 2009; Chagpar et al, 2011; Tausch et al, 2012).
One of the most controversial issues regarding the treatment of
breast cancer is defining the indications of post-mastectomy
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radiation therapy (PMRT). A general consensus has been reached
to advise PMRT for patients with four or more involved axillary
nodes (Recht et al, 2001; Goldhirsch et al, 2009, 2011); however,
the role of PMRT in patients with pN1 disease is still widely
debated (Ragaz et al, 1997; Overgaard et al, 1999; Ragaz et al, 2005;
Smith et al, 2005; Nielsen et al, 2006; Overgaard et al, 2007; Kim
et al, 2011).
In this study, we hypothesised that patients with pN1 disease
might consist of heterogeneous prognostic subsets of patients and
that the LNR might be used to improve the prognostication.
Furthermore, we tested LNR as a potential discriminator of
patients with a higher risk who might benefit from subsequent
PMRT.
PATIENTS AND METHODS
The Korean breast cancer registry. All data used in this study
were retrieved from the Korean Breast Cancer Registry (KBCR),
which has prospectively maintained an online database to store
information on each patient’s Korean personal identification
number, age, type of surgery, primary tumour size, number of
positive/dissected nodes, oestrogen receptor (ER)/progesterone
receptor (PR) status, histologic grade, and details of adjuvant
therapy. Nation-wide collaborative efforts from 102 general
hospitals, including 41 university hospitals, have contributed to
the KBCR database since 1996 (Ahn et al, 2007). Exploiting the
patient’s identification number as a unique identifier, we
amalgamated the KBCR database with two population-based
sources of information: the Korean Central Cancer Registry, which
provides patient’s survival data, and the Korean National Statistical
Office, which publishes complete death statistics.
Cut-off values of the LNR. To define the optimal cutoff values of
LNR, we first investigated the prognostic value of LNR as a
continuous variable. Using multivariate Cox proportional hazards
regression models, we assessed the statistical significance of the
LNR adjusted for clinico-pathologic characteristics including age,
tumour size, ER/PR status, histologic grade, and PMRT. As a next
step, we carefully identified the upper and lower cutoff values of
the LNR to classify breast cancer patients into three distinct
subgroups: low, intermediate, and high. These optimal cutoff
values were intended to minimise information loss by categorising
the continuous variable of the LNR (categorised LNR, cLNR). All
possible combinations of lower and upper cutoff values ranging
from 0.001 to 0.85 with an increment of 0.001 were considered.
The robustness of the estimated cutoff values was examined using
the nonparametric bootstrap method (Efron, 1979) with generation
of 10 000 bootstrap samples to attain the empirical sampling
distributions of the estimated cutoff values.
Identification of the optimal cutoff points of the LNR was based
on a population of primary breast cancer patients who had at least
one positive axillary lymph node and underwent definitive
mastectomy between 1998 and 2009. All of the patients received
anthracycline- and taxane-based adjuvant chemotherapy according
to the NCCN (National Comprehensive Cancer Network) guide-
line (Carlson et al, 1996). For reliable estimation of nodal
involvement, patients who had fewer than 10 dissected lymph
nodes were excluded. We also excluded patients who received
neoadjuvant chemotherapy or breast conservation therapy, and
those with ductal carcinoma in situ or stage IV disease at the time
of diagnosis. As a result, a total of 7741 patients were analysed to
define the optimal cutoff values of LNR.
Study population patients with pN1 disease. In this study, we
intended not only to evaluate the prognostic value of the LNR but
also, more importantly, to identify patients with a higher risk with
pN1 disease who would benefit from PMRT after definitive initial
surgery. Therefore, we restricted our study population to 3817
patients who had one to three pN1. To address the current
controversy regarding PMRT, we further limited the study
population to a patient cohort with T1/T2 lesions. A total of
3477 patients with pN1 disease and small tumours (T1/T2), who
were treated with or without PMRT, were ultimately enrolled as
our main study population. Post-mastectomy radiation therapy
covered chest wall and regional lymph nodes in each patient.
Irradiated volume was treated with 4 or 6-MV photons and/or
electrons with median radiation dose of 50–50.4ere with 1.8–2wit
per fraction. Regional lymph nodes include supraclavicular, high,
and a part of low axillary lymph nodes. Internal mammary lymph
nodes were included depending on physician’s preference.
Focusing on these patients with pN1 disease, we first evaluated
the prognostic value of the cLNR adjusted for clinico-pathologic
characteristics and then investigated the clinical relevance of cLNR
with respect to PMRT.
Statistics. The primary end point of this study was overall survival
(OS) defined as the time from the date of surgery to death of any
cause. According to the Akaike Information Criteria, the
independent prognostic factors significantly associated with OS
were selected in stepwise manner avoiding over-parameterisation.
The treatment effect of PMRT in patients with pN1 disease was
assessed for each of the cLNR groups using the likelihood ratio test.
Based on the log-rank test, the Kaplan–Meier OS estimates of the
cLNR groups were also compared with measure, the unadjusted
treatment effects of PMRT. P-values o0.05 were considered
statistically significant. All statistical analyses were performed
using R (http://www.r-project.org). This study was approved by the
Korean Breast Cancer Registry Committee and the Institutional
Review Boards of Severance Hospital.
RESULTS
Cutoff values of LNR. According to the multivariate analysis, the
continuous variable of the LNR was the independent prognostic
factor most significantly associated with OS (hazard ratio (HR),
7.57; 95% confidence interval (CI), 5.83–9.82; Po0.0001;
Supplementary Table 1). On verification of the prognostic value
of the LNR, the optimal lower and upper cutoff values of LNR were
estimated to be 0.18 and 0.64, respectively. According to the
empirical sampling distribution of the estimated cutoff values
based on 10 000 bootstrap samples, the most frequent values were
observed around 0.18 and 0.64, respectively (lower cutoff:
mean¼ 0.18, s.e.¼ 0.02; upper cutoff: mean¼ 0.64, s.e.¼ 0.06;
Figure 1).
Prognostic value of the categorised LNR in patients with pN1
disease. The characteristics of the study population with pN1
disease are summarised in Table 1. Among a total of 3477 patients,
1255 (36.1%) and 2222 (63.9%) patients had T1 and T2 lesions,
respectively. The mean number of dissected lymph nodes was
18.76 (s.d., 7.27). The number of patients with one, two, and three
pN1 was 1699 (48.9%), 1049 (30.2%), and 729 (21.0%),
respectively. As our main study population excluded patients
who had fewer than 10 dissected lymph nodes, the values of the
LNR ranged from 0 to 0.3. Using the lower cutoff value of 0.18,
3059 (88.0%) and 418 (12.0%) patients were assigned into the low
and intermediate cLNR groups, respectively.
The median follow-up time was 3.3 years. Based on the
multivariate analysis, younger age (o35 years), large tumour size
(T2 lesion), negative ER/PR status, and high histologic grade
(II and III) were significantly associated with poor OS (Table 2).
The cLNR was also a significant independent prognostic factor.
Compared with the low cLNR group, the adjusted HR of the
intermediate cLNR group was 1.81 (95% CI, 1.34–2.45, P¼ 0.0001;
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Table 2). There was a statistically significant separation between
the Kaplan–Meier survival curves of the low and intermediate
cLNR groups (P¼ 0.0018) (Figure 2). The estimated survival rate
at 10 years was higher in the low cLNR group (76.7%) than in the
intermediate cLNR group (61.4%).
Predictive value of categorised LNR for efficacy of PMRT in
patients with pN1 disease. The study population included
443 (12.7%) patients who received PMRT after mastectomy. As
indicated by the interaction terms between PMRT and the
cLNR groups, there was a significant benefit of PMRT for the
intermediate cLNR group (likelihood ratio test, P¼ 0.0248;
Table 2). In contrast, there was no apparent benefit of PMRT
for patients with a low cLNR (likelihood ratio test, P¼ 0.2415).
For patients with an intermediate cLNR, PMRT significantly
reduced relative risk (HR, 0.39; 95% CI, 0.17–0.89) and absolute
risk (25.48%; s.e., 15.36%; Supplementary Figure 1).
As expected, for the intermediate cLNR group PMRT greatly
increased the estimated survival rate at 10 years from 56.13% to
81.61% (Table 3, Figure 3C), and Kaplan–Meier survival curves
according to PMRT or no PMRT indicated a statistically significant
difference (P¼ 0.0047). In contrast, there was no significant
increase in the estimated survival rates at 10 years for patients with
PMRT in the low cLNR group (76.47% vs 79.10; Table 3,
Figure 3B) and in the whole study population with pN1
disease (74.35% vs 79.48%; Table 3, Figure 3A). Consistent
with these findings, PMRT did not have a significant effect on
the Kaplan–Meier survival curves for the low pLNR group
(P¼ 0.0706) or for all patients with pN1 disease (P¼ 0.6033).
DISCUSSION
The presence of axillary lymph node metastasis is the single most
important prognostic factor in patients with breast cancer (Carter
et al, 1989; Fitzgibbons et al, 2000; Vinh-Hung et al, 2003a), and
the prognostic importance of the total number of pN1 has long
been recognised (Carter et al, 1989; Fisher et al, 1993; Recht et al,
1999; Fitzgibbons et al, 2000; Edge, 2010). The latest AJCC staging
system defined patients with one to three positive axillary lymph
nodes as pN1 disease (Singletary et al, 2002; Edge, 2010), while
patients with more than four positive axillary lymph nodes are
classified as pN2 or pN3. Although patients with pN2 or pN3
disease have a clearly worse prognosis than those with pN1 disease
(Axelsson et al, 1992; Kim et al, 2006), the biologic rationale for
four nodes as the threshold between pN1 and pN2 is unclear.
We hypothesised that patients with pN1 disease might comprise
different prognostic subsets of patients, mainly for the following
two reasons: first, in past analysis of the SEER (Surveillance,
Epidemiology and End Results) database, (Vinh-Hung et al 2003a)
reported that the relative mortality hazard continues to increase
with each involved node without any obvious cutoff point. Second,
the current staging system of breast cancer is based merely on the
number of pN1 without considering the total number of lymph
nodes dissected. In cases where only a few lymph nodes are
examined, there is the potential possibility of downstaging the
axilla (Vinh-Hung et al, 2009; Danko et al, 2010).
The LNR has been proposed as an alternative measure to
improve the prognostication system in patients with node-positive
disease (Vinh-Hung et al, 2003a, b; Voordeckers et al, 2004;
Truong et al, 2005a; Kuru, 2006; Woodward et al, 2006; Truong
et al, 2008; Vinh-Hung et al, 2009; Danko et al, 2010; Chagpar
et al, 2011; Tausch et al, 2012). Compared with the number-based
staging system, the ratio-based staging system exploits additional
information on the total number of lymph nodes dissected.
However, the use of additional information does not rule out the
issue of misclassification. For example, if the total number of
lymph nodes removed is very small, a high LNR may result from
insufficient dissection of the axillary lymph node. In this case, the
ratio-based staging system may result in upstaging of patients.
For reliable estimation of nodal involvement by the LNR, it
would be desirable to define a minimum number of dissected
lymph nodes. Previous observational studies have shown that
sampling fewer than 10 axillary nodes more than doubles the risk
of subsequent loco-regional failure (Recht et al, 1999; Katz et al,
2000, 2001; Woodward et al, 2003), and that the estimation of
nodal involvement is more reliable when at least 10 nodes are
excised (Fisher et al, 2002). The AJCC requires that a minimum of
six axillary lymph nodes be removed and examined whereas other
authorities recommend that at least 10 lymph nodes be examined
(National Institutes of Health, 1991; The Steering Committee,
1998). To ensure that patients in this study received appropriate
axillary dissection, we restricted the study population to patients
who had a minimum of 10 dissected lymph nodes.
We initially aimed to evaluate the clinical value of the LNR
among patients with pN1 disease. As a preliminary step, we
confirmed the prognostic value of the LNR as a continuous
variable for all node-positive patients using multivariate Cox
regression analysis (Supplementary Table 1). Subsequently, we
categorised the LNR by lower and upper cutoff values of 0.18 and
0.64, respectively, and all node-positive patients were assigned
into low, intermediate, and high cLNR groups, respectively.
As expected, there were significant separations among the
Kaplan–Meier OS estimates for the three cLNR groups
(Po0.0001; Supplementary Figure 2).
Next, we evaluated the clinical value of the cLNR, focusing on
patients with pN1 disease. For patients with pN1 disease, the LNR
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Figure 1. Empirical distributions of the estimated LNR cutoff values
based on 10 000 bootstrap samples: (A) lower cutoff; (B) upper cutoff.
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ranged from 0 to 0.3 because only patients with at least 10 dissected
nodes were included in our study population. As a result, all of the
patients with one positive node were assigned into the low cLNR
group, while patients having two and three positive nodes were
assigned into low and intermediate cLNR groups according to the
total number of dissected nodes. By multivariate analysis, we
demonstrated that the cLNR further classified patients with pN1
disease into two heterogeneous prognostic subsets, with patients in
the intermediate cLNR group having a clearly worse prognosis
than those in the low cLNR group in terms of OS.
After ascertaining that the cLNR was indeed significantly
associated with OS, we further investigated the treatment effects of
PMRT in patients with pN1 disease. A clear survival benefit of
PMRT was observed in patients assigned to the intermediate cLNR
group, in which PMRT was associated with a 61% reduction in
overall mortality (Table 2). Truong et al (2005b) also suggested
that the percentage of node positive (425% of removed nodes)
were statistically significant independent factors associated with
greater loco-regional recurrence, meriting consideration of PMRT
in patients with pN1 and T1/T2 disease.
Currently, the general consensus is that PMRT is indicated for
patients with four or more involved axillary nodes. However, there
is no agreement on whether all patients with pN1 disease should be
recommended for PMRT (Recht et al, 2001; Goldhirsch et al, 2009,
2011). The previous retrospective study using the SEER database
reported no remarkable survival benefit of PMRT for patients with
pN1 disease (Smith et al, 2005). However, according to the latest
analysis of the Early Breast Cancer Trialists’ Collaboration Group,
PMRT reduced local recurrence risk and mortality in patients with
node-positive disease regardless of the degree of nodal involvement
(Clarke et al, 2005). More importantly, recent randomised
prospective trials demonstrated improved survival after PMRT in
all node-positive women (Ragaz et al, 1997; Overgaard et al, 1999;
Ragaz et al, 2005; Nielsen et al, 2006), and the survival increment
was at least equally beneficial in patients with pN1 disease
(Overgaard et al, 2007). Despite the level 1 evidence of the above
Table 1. Comparison of clinico-pathologic factors between patients with PMRT and without PMRT
All patients (n¼3477) PMRT (n¼443) No PMRT (n¼3034)
n % n % n % P-value
Age
p35 300 8.6 53 12 53 12 0.0097
435 3177 91.4 390 88 390 88
Sex
Male 20 0.58 2 0 2 0 0.9742
Female 3457 99.4 3016 100 3016 100
T stage
T1 1255 36.1 158 35.7 158 35.7 0.8823
T2 2222 63.9 285 64.3 285 64.3
No. of dissected lymph nodes Mean¼18.76, s.d.¼ 7.27 Mean¼18.19, s.d.¼6.76 Mean¼18.84, s.d.¼ 7.34 0.0597
No. of positive node
1 1699 48.9 148 33.4 148 33.4 o0.0001
2 1049 30.2 148 33.4 148 33.4
3 729 21.0 147 33.2 147 33.2
Histologic grade
I 386 11.1 47 10.6 47 10.6 0.7857
II, III 3091 88.9 396 89.4 396 89.4
Oestrogen receptor
Negative 1268 36.5 167 37.7 167 37.7 0.6012
Positive 2209 63.5 276 62.3 276 62.3
Progesterone receptor
Negative 1516 43.6 178 40.2 178 40.2 0.1329
Positive 1961 56.4 265 59.8 265 59.8
Endocrine therapy
None 1355 39 169 38.1 169 38.1 0.7434
Done 2122 61 274 61.9 274 61.9
cLNR
Low (p0.18) 3059 88 349 78.8 349 78.8 o0.0001
Intermediate (0.18–0.3) 418 12 94 21.2 94 21.2
Abbreviations: cLNR¼ categorised lymph node ratio; PMRT¼post-mastectomy radiation therapy.
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randomised trials supporting the benefits of PMRT, it should be
noted that these randomised trials have been criticised for their less
extensive axillary surgery and relatively high risk of loco-regional
recurrence (Overgaard et al, 1997, 1999; Recht et al, 1999;
Katz et al, 2000; Woodward et al, 2003; Ragaz et al, 2005;
Nielsen et al, 2006). As such, we believe that interpretation of the
benefit of PMRT should be limited to patients with fewer than
10 dissected lymph nodes. The ongoing randomised MRC/EORTC
SUPREMO trial is designed to evaluate the results of chest
wall irradiation in the management of the patients who under-
went MRM with pN1 disease. It may provide us better infor-
mation regarding the role of PMRT in this patient group (Kunkler
et al, 2008).
According to results of this study, we suggest that the
indications of PMRT in patients with pN1 disease are as follows:
first, among patients with at least 10 dissected lymph nodes, PMRT
should be recommended for patients with two and three positive
nodes, who would be classified into an intermediate cLNR group.
Second, an additional survival benefit of PMRT is less clear for
patients with one positive lymph node and at least 10 dissected
lymph nodes.
The inherent limitation of this retrospective study is that
patients were assigned to PMRT without randomisation, and it is
therefore possible that unrecognised biases might influence our
results. Nevertheless, most of the clinico-pathologic characteristics
such as T stage, histologic grade, ER/PR, and number of dissected
node were well-balanced between the two groups of patients with
or without PMRT (Table 1). However, we did find that patients
with three positive nodes and younger age were more likely to
receive PMRT and consequently the patients who were treated
with PMRT might have been biased toward having a worse
prognosis. This limitation of our study was in part balanced by
several strengths. First, LNR research to date has been limited
because there is no clear consensus about the cutoff points and
many researchers have therefore used their own criteria
(Voordeckers et al, 2004; Truong et al, 2005a; Kuru, 2006;
Truong et al, 2008; Danko et al, 2010; Chagpar et al, 2011; Tausch
et al, 2012). However, we objectively determined robust cutoff
values using a nonparametric resampling method that does not
require any predefined assumptions or distributional specifica-
tions. Second, this study not only evaluated the prognostic value of
the cLNR, but also tested the clinical benefit of PMRT in patients
with pN1 disease. To the best of our knowledge, there has been no
previous report explicitly using cLNR as a predictive marker
for PMRT, especially focusing on patients with pN1 disease. Third,
the data analysed in this study were retrieved from the nation-wide
KBCR. Therefore, we could minimise the selection bias often
created by sampling from a single institution. Finally, all of the
patients included in this study were treated with systemic adjuvant
chemotherapy, thus avoiding biases related to systemic treatment
that might affect evaluation of the benefit of PMRT.
In conclusion, our study showed that the cLNR enhanced risk
stratification in patients with pN1 disease and that patients with
intermediate cLNR had a worse prognosis than those with low
cLNR. The cLNR also identified a subgroup of patients with pN1
Table 2. Multivariate analysis of overall survival of breast cancer patients
with pN1 disease
Variable Hazard ratio 95% CI P-value
Age, X36 0.55 0.41–0.74 o0.0001
Tumour size, T2 1.31 1.02–1.67 0.0336
Oestrogen receptor, positive 0.68 0.53–0.89 0.0042
Progesterone receptor, positive 0.54 0.42–0.71 o0.0001
Histologic grade, II and III 1.65 1.03–2.63 0.0380
cLNR, intermediate 1.81 1.34–2.45 0.0001
cLNR, low: PMRT, yes 1.25 0.86–1.82 0.2415
cLNR, intermediate: PMRT, yes 0.39 0.17–0.89 0.0248
Abbreviations: CI¼ confidence interval; cLNR¼ categorised lymph node ratio;
PMRT¼post-mastectomy radiation therapy; pN1¼positive lymph nodes.
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Figure 2. Kaplan–Meier OS estimates of breast cancer patients with
pN1 disease according to the cLNR risk groups.
Table 3. Kaplan–Meier overall survival estimates at 10 years for patients with pN1 disease classified by the cLNR risk groups
PMRT: no PMRT: yes
Group No. of patients 10-Year OS (%) 95% CI No. of Patients 10-Year OS (%) 95% CI No. of Patients
All patients 3477 74.35 70.93–77.93 3034 79.48 73.11–86.40 443
Low cLNR 3059 76.47 73.01–80.10 2710 79.10 71.81–87.14 349
IntermediatecLNR 418 56.13 43.40–72.58 324 81.61 69.78–95.45 94
Abbreviations: CI¼ confidence interval; cLNR¼ categorised lymph node ratio; OS¼overall survival; PMRT¼post-mastectomy radiation therapy; pN1¼positive lymph nodes.
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disease who would respond better to PMRT. Provided appropriate
axillary dissection is satisfied as a prerequisite, PMRT should be
recommended for patients with two or three positive nodes who
belong to the intermediate cLNR group.
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Figure 3. Kaplan–Meier OS estimates of breast cancer patients with pN1 disease according to PMRT: (A) all patients with pN1 disease; (B) patients
with the low cLNR; and (C) patients with the intermediate cLNR. *Indicates P-value adjusted for multiple comparisons using Tukey’s procedure.
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